P620 Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease

Inflammatory bowel disease (IBD) is a group of chronic relapsing inflammatory disorders affecting the large and small intestine, with a rising worldwide incidence and prevalence. Anaemia is the most common extraintestinal manifestation of IBD, correlating with disease activity, and tending to relapse even after successful therapy. Iron deficiency is the most common cause; however, it often manifests in combination with anaemia of inflammation. As such, multiple parameters are used for the diagnosis of iron deficiency anaemia in IBD. Timely recognition and selection of appropriate therapy leads to an improvement in the quality of life and prevention of potential sequelae. Oral iron can be effective under specific circumstances; however, as luminal iron changes microbiota and bacterial metabolism, oral administration should be avoided. Intravenous iron is preferred as it bypasses the sites of inflammation. Nevertheless, the optimization of IBD treatment should occur simultaneously, as this improves both patient condition and response to iron therapy. Herein, we discuss the screening, diagnosis, selection of therapy, and follow-up for iron deficiency anaemia in IBD.

Download Full-text

P456 Comparative analysis of oral versus intravenous iron in patients with inflammatory bowel disease and iron deficiency/anaemia – impact on hospitalisation in Germany

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjx002.581 ◽

2017 ◽

Vol 11 (suppl_1) ◽

pp. S309-S310

Author(s):

K. Borchert ◽

T. Hardt ◽

J.S. Haas ◽

S.H. Ong ◽

E. Lechat ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Comparative Analysis ◽

Iron Deficiency ◽

Bowel Disease ◽

Iron Deficiency Anaemia ◽

Intravenous Iron ◽

Deficiency Anaemia ◽

Inflammatory Bowel

Download Full-text

Comparison between intravenous iron gluconate alone and intravenous iron gluconate plus levofolinic acid for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease

Digestive and Liver Disease ◽

10.1016/s1590-8658(06)80340-3 ◽

2006 ◽

Vol 38 ◽

pp. S127

Author(s):

A. Papa ◽

S. Danese ◽

S. Guglielmo ◽

I. Roberto ◽

M. Covino ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Iron Deficiency ◽

Bowel Disease ◽

Iron Deficiency Anaemia ◽

Intravenous Iron ◽

Deficiency Anaemia ◽

Inflammatory Bowel

Download Full-text

P420 Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemia

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.544 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S424-S425

Author(s):

F Akriche ◽

I Jacob ◽

C Schmidt ◽

S Howaldt

Keyword(s):

Inflammatory Bowel Disease ◽

Iron Deficiency ◽

Bowel Disease ◽

Iron Deficiency Anaemia ◽

Significant Proportion ◽

Efficacy And Safety ◽

Childbearing Age ◽

Deficiency Anaemia ◽

Significant Difference ◽

Inflammatory Bowel

Abstract Background The efficacy and safety of ferric maltol (FM) has been demonstrated in inflammatory bowel disease (IBD) patients with mild-to-moderate iron deficiency anaemia (IDA; haemoglobin [Hb] ≥ 9.5 g/dL). New data are available from a recent open-label, Phase 3b non-inferiority study comparing the efficacy and safety of FM to ferric carboxymaltose for IBD patients with more severe IDA (Hb at screening: 8.0 - 11.0/12.0 g/dL [women/men]) (NCT02680756). Though the primary endpoint was not met, this post hoc analysis aimed to utilise patient-level data to confirm the efficacy and safety of FM in patients with baseline Hb < 9.5 g/dL. Methods Patients assigned to FM (N=125) were grouped based on baseline Hb: <9.5 g/dL (n=38) and ≥9.5 g/dL (n=87). Univariate and multivariate analyses were performed for primary (Week 12 change from baseline [CFB] Hb) and key secondary endpoints (Week 12 responder rate [≥2 g/dL Hb increase or Hb normalisation] and long-term efficacy). Safety analysis was performed. Results Overall, demographic characteristics were broadly comparable with a greater, but not significant, proportion of females (63.2% vs. 50.6%), women of childbearing age (75.0% vs. 63.6%) and active Crohn’s disease (37.5% vs. 32.7%) in patients with baseline Hb < 9.5 g/dL vs. ≥ 9.5 g/dL, respectively. Mean baseline Hb was 8.6 g/dL in patients with baseline Hb < 9.5 g/dL and 10.6 g/dL in patients with baseline Hb ≥ 9.5 g/dL. There was no significant difference in mean CFB Hb at Week 12 (2.92 g/dL vs. 2.35 g/dL, p=0.960) and Week 12 responder rates (70.0% vs. 67.1%, p=0.523) in patients with baseline Hb < 9.5 g/dL and ≥ 9.5 g/dL, respectively. Mean CFB Hb was numerically but not significantly higher in patients with baseline Hb < 9.5 g/dL at every visit up to Week 52 (Table 1). Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. Conclusion FM achieved consistent and clinically meaningful increases in Hb in patients with baseline Hb < 9.5 g/dL that were comparable to patients with Hb ≥ 9.5 g/dL. No safety differences were identified between both groups. These data suggest that FM is effective and well tolerated in IBD patients with IDA regardless of baseline Hb.

Download Full-text